01 February, 2010

Develop and License Your H1N1 Biological

Don't fall behind your peers. Benchmark Biolabs leads the industry in accelerating H1N1 efforts towards commercially licensed products. Take advantage of your fastest route to market.

Broad experience and assets available for your benefit

Benchmark has successfully demonstrated our H1N1 study capabilities across a variety of biological approaches as companies have sought to gain regulatory approval. By utilizing Benchmark, our clients immediately have access to:

• Model Development across multiple species-ferrets, mice, pigs, cats, dogs, guinea pigs, poultry
• Demonstration of vaccine efficacy using clinical H1N1 challenge
• Multiple sample collection and analysis methods
• Assay development and reagent production
• On-site analytical assays, decreasing possible errors associated with sample transport testing
• In Vitro assay capability, both HA and HAI
• In Ovo inoculation, hatching, post-hatch challenge
• Cell-based assay capability, as well as neutralization and expansion
• Real time PCR capability
• Sequence analysis for homology
• Antibody testing for potential cross-reactive protection
• Management of relevant transport permits and other approvals as necessary to ship and receive influenza materials and strains

Benchmark currently possesses the following bank of relevant strains for testing:

Take advantage of our services

Benchmark's facilities and experienced personnel remain available to accept new projects, but the calendar is filling fast. Contact us for more information regarding your needs toward licensing your influenza asset.

We will have your solution.

Thomas D. Overbay, DVM
Vice President, Business Development
Benchmark Biolabs
(402) 475-8104 Office
(402) 475-8511 Fax
toverbay@benchmarkbiolabs.com

For more information, visit our web site: www.benchmarkbiolabs.com
Copyright © Benchmark All rights reserved.